DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
Rhea-AI Summary
DarioHealth (NASDAQ: DRIO) announced publication of a peer-reviewed retrospective cohort study in Journal of Medical Internet Research showing estimated real-world savings and lower utilization for adults with type 2 diabetes using the Dario digital health platform versus matched usual-care individuals.
Key findings: 23.5% lower inpatient hospitalization rates, 26% lower all-cause healthcare resource utilization charges, and an estimated $5,077 gross medical cost savings per patient per year. The 12-month analysis covered 2,445 Dario users vs 7,334 matched controls and reported shorter lengths of stay, lower 30-day readmissions, and a dose-response link between engagement and fewer inpatient/ER events.
Positive
- $5,077 estimated gross medical cost savings per patient per year
- 23.5% lower inpatient hospitalization rates for Dario users
- 26% lower all-cause HCRU charges for Dario users
- Study analyzed 12-month outcomes for 2,445 users vs 7,334 matched controls
Negative
- Study design was a retrospective cohort, an observational analysis rather than a randomized trial
News Market Reaction – DRIO
On the day this news was published, DRIO declined 7.23%, reflecting a notable negative market reaction. Argus tracked a trough of -12.6% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $90M at that time.
Data tracked by StockTitan Argus on the day of publication.
Sanofi and Symphony Health teams conducted the study demonstrating how Dario's digital, diabetes intervention platform reduces real-world healthcare burden and cost compared to usual care
Representing a high-rigor, real world analysis, the study found Dario users, as compared to matched individuals receiving usual care, had
More frequent engagement on the Dario platform associated with fewer inpatient and ER events
The direct medical cost of diabetes in the
This rigorous, third-party analysis directly addresses one of the most important questions that payers and employers have for their solution partners, namely: Do digital interventions reduce real-world healthcare burden and cost compared to people already receiving usual care? The study's authors found that Dario users had consistently lower utilization rates and charges than matched individuals receiving usual care.
The study examined 12-month outcomes for 2,445 adults with type 2 diabetes using Dario's platform compared to 7,334 matched individuals receiving usual care. Unlike many digital health evaluations that rely on pre/post comparisons, this study used a high-stringency matched-cohort design drawing from a large real-world claims database – representing one of the most rigorous economic evaluations of a digital health solution to date. Additionally, most digital health studies compare effects between treated and non-treated groups, which tends to inflate the impact of an intervention. The higher bar of comparing an intervention group to a group receiving usual care is far less common.
Across multiple measures of healthcare utilization, charges and estimated costs, Dario users demonstrated consistently lower burden compared to a matched group receiving usual care:
23.5% lower inpatient hospitalization rates9.3% lower all-cause healthcare resource utilization (HCRU)
(inpatient hospitalizations + emergency room visits)26% lower all-cause HCRU charges- Estimated gross cost savings of
$5,077 - Shorter inpatient lengths of stay
- Lower 30-day readmission rates
- A strong dose-response relationship, with more frequent engagement on the Dario platform associated with fewer inpatient and ER events
Collectively, these findings reinforce that a holistic digital platform integrating connected devices, behavior-change science and real-time engagement can meaningfully reduce avoidable utilization – delivering benefits beyond what is typically achieved in usual care alone.
The results add to the growing body of evidence supporting Dario's approach and its ability to help employers, payers and health systems improve chronic condition management while reducing the cost of care.
"Real-world economic validation from peer-reviewed research is critical for organizations evaluating digital health solutions," said Yifat Hershcovitz, PhD, Vice President of Clinical and Scientific Affairs at Dario. "This study shows that when members engage with Dario's connected devices, personalized guidance and behavioral support, the impact on reducing costly hospital and ER events can be both meaningful and sustained."
"This study shows what matters most to health plans and employers: when enterprises use a well-designed digital intervention, they can reduce avoidable hospitalizations and lower the cost of care, even for populations already receiving care," added Omar Manejwala, MD, Chief Medical Officer at Dario. "This study provides some of the strongest evidence to date that employers and health plans can have confidence in Dario's financial impact."
The full article is available open access on the JMIR website: https://www.jmir.org/2025/1/e67320/
About DarioHealth Corp. (NASDAQ: DRIO)
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the Company's potential addressable market, the benefits to be realized by the Company's integrated digital solution for employers and members, that the analysis is a critical milestone for the Company, that the Company's digital care can deliver meaningful and sustainable results that matter to both patients and payers, the belief that the study shows that when members engage with Dario's connected devices, personalized guidance and behavioral support, the impact on reducing costly hospital and ER events can be both meaningful and sustained, the belief that the study provides some of the strongest evidence to date that employers and health plans can have confidence in Dario's financial impact. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the
DarioHealth Corporate Contacts
Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310
Rob Halpern
SVP Marketing
irteam@dariohealth.com
Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:SOURCE DarioHealth Corp.
FAQ
What did the JMIR study published on Nov 24, 2025 find about DarioHealth (DRIO) medical cost savings?
How much did hospitalizations change for DarioHealth (DRIO) users in the Nov 2025 JMIR study?
What sample size did the Nov 2025 JMIR study use to evaluate DarioHealth (DRIO)?
Did the JMIR study link DarioHealth (DRIO) engagement to clinical events?
Are the JMIR results for DarioHealth (DRIO) from a randomized trial?
